News Related to CTCL

Related coverage linked through entity extraction aliases.

Citius Oncology Reports LYMPHIR Revenue and Positive Phase 1 CAR-T Combination Data

Mar 04, 2026

Citius Pharmaceuticals reported $3.9 million in first revenue from LYMPHIR's December 2025 launch for cutaneous T-cell lymphoma, while subsidiary Citius Oncology announced positive Phase 1 data showing 86% response rate when LYMPHIR was administered prior to CAR-T therapy in high-risk lymphoma patients.

Global Oncology Market Projected to Reach $748 Billion by 2035 Amid Immunotherapy Growth

Feb 19, 2026

The global oncology market is projected to grow from $280 billion in 2026 to $748 billion by 2035 at 11.54% CAGR, driven by rising cancer incidence, precision medicine expansion, and strong immunotherapy pipelines across multiple tumor types.